Related Experiment Video
Updated: Jun 18, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Tenascin-C as a prognostic biomarker in osteosarcoma?
Wei Xiong1, Peng-yan Niu, Wen-tao Zhu
1Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Chinese Medical Journal
|December 3, 2009
Summary
Tenascin-C, an extracellular matrix protein, is downregulated in metastatic osteosarcoma. Low Tenascin-C expression in patients correlates with poorer survival, suggesting its role in osteosarcoma progression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Metastatic osteosarcoma treatment remains challenging.
- Extracellular matrix (ECM) proteins are crucial in osteosarcoma progression and tumor microenvironment.
- Identifying key ECM genes is vital for understanding osteosarcoma and patient outcomes.
Purpose of the Study:
- To identify and characterize extracellular matrix (ECM) genes involved in osteosarcoma progression.
- To investigate the association of these ECM genes with patient survival in osteosarcoma.
Main Methods:
- Oligonucleotide microarray and gene ontology analysis of osteosarcoma cell lines (MG63 and MG63-A1).
- Validation of candidate gene expression using RT-PCR and Western blotting.
- Immunohistochemistry on 37 osteosarcoma specimens to assess clinical relevance.
Main Results:
- Tenascin-C, an ECM component, was significantly downregulated in highly metastatic osteosarcoma cells (MG63-A1) compared to parental cells (MG63-wt).
- Validation confirmed Tenascin-C downregulation at both mRNA and protein levels.
- Low Tenascin-C expression (<20%) in osteosarcoma tissues correlated with poor patient survival.
Conclusions:
- Tenascin-C expression levels are associated with osteosarcoma patient survival.
- Further research is needed to elucidate the functional role and molecular mechanisms of Tenascin-C in osteosarcoma progression.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...